Spots Global Cancer Trial Database for cetrelimab
Every month we try and update this database with for cetrelimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | NCT04592237 | Aggressive Vari... Castration-Resi... Metastatic Pros... Metastatic Pros... Metastatic Pros... Stage IV Prosta... | Cabazitaxel Carboplatin Cetrelimab Niraparib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder | NCT04919512 | Urinary Bladder... | TAR-200 Cetrelimab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer | NCT05818683 | Metastatic Cast... | JNJ-78278343 Cetrelimab Cabazitaxel Docetaxel Apalutamide Enzalutamide Darolutamide Abiraterone ace... | 18 Years - | Janssen Research & Development, LLC | |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | NCT04926181 | Small Cell Neur... Prostate Cancer Small Cell Carc... | Apalutamide Cetrelimab | 18 Years - | University of California, San Francisco | |
| A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors | NCT06311578 | Advanced Solid ... | JNJ-87704916 Cetrelimab | 18 Years - | Johnson & Johnson Enterprise Innovation Inc. | |
| A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | NCT04640623 | Urinary Bladder... | TAR-200 Cetrelimab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | NCT04640623 | Urinary Bladder... | TAR-200 Cetrelimab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | NCT03473743 | Urothelial Carc... | Erdafitinib Cetrelimab Cisplatin Carboplatin | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | NCT03473743 | Urothelial Carc... | Erdafitinib Cetrelimab Cisplatin Carboplatin | 18 Years - | Janssen Research & Development, LLC | |
| A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | NCT04658862 | Urinary Bladder... | Cetrelimab TAR-200 Cisplatin Gemcitabine Conventional ra... Hypo-fractioned... | 18 Years - | Janssen Research & Development, LLC | |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | NCT04926181 | Small Cell Neur... Prostate Cancer Small Cell Carc... | Apalutamide Cetrelimab | 18 Years - | University of California, San Francisco |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
